ORGS Orgenesis Inc

Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit Europe. The conference, renowned for gathering leading professionals to advance the manufacturing and quality control of biological and genetic therapies, will take place in Barcelona from March 19th to 21st, 2024.

Ms. Caplan is scheduled to present on Tuesday, March 19th, at 2:10 PM CET. In her presentation, titled "Overcoming Conventional CGT Processing Challenges with Point-of-Care (POCare) Solutions," Caplan will discuss how the Company’s POCare solutions, leveraging the latest technology and data advances, can overcome conventional CGT processing challenges and enable standardization. The focus will be on closed, automated, and reproducible processes to bring treatments closer to patients, enabling standardization and making these innovative therapies more affordable and accessible worldwide.

Following the presentation, Caplan will participate in a panel discussion at 3:10 PM CET, titled "The Role of Decentralized vs. Centralized Manufacturing." The panel, moderated by Angela Osborne, Ph.D., CEO & Founder of eXmoor Pharma Concepts Ltd., will explore the critical role of local academic/hospital GMP centers in the industry's inception and the necessity for alternative solutions to ensure therapies reach all patients in need. The discussion aims to shed light on the evolving landscape of manufacturing and supply in the CGT field.

Bioprocessing Summit Europe brings together 750+ upstream, downstream, bioproduction, analytical and formulation professionals. This 3-day, 12-track meeting has quickly become a premier meeting in the European bioprocessing calendar and is regarded by many as “the fastest growing bioprocessing meeting in Europe” following record growth in 2023.

About Orgenesis

Orgenesis is a global biotech company that has been committed to unlocking the potential of cell and gene therapies (CGTs) since 2012 as well as a paradigm-shifting decentralized approach to processing since 2020. This new model allows Orgenesis to bring academia, hospitals, and industry together to make these essential therapies a reality sooner rather than later. Orgenesis is focusing on advancing its CGTs toward eventual commercialization, while partnering with key industry stakeholders to provide a rapid, globally harmonized pathway for these therapies to reach and treat a larger number of patients more cost effectively and with better outcomes through great science and decentralized production. Additional information about the Company is available at: www.orgenesis.com.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the expected consolidation of Octomera in our consolidated financial statements, our reliance on, and our ability to grow, our decentralized cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our decentralized cell therapy processing, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Investor relations contact for Orgenesis:Crescendo Communications, LLCTel: 212-671-1021Email: orgs@crescendo-ir.com

Communications contact for Orgenesis:IB CommunicationsNeil Hunter / Michelle Boxall